The role of GLP-1 receptor agonists in the management of obesity

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian health care system.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup